Lorenzo Galluzzi Selected Research

Oncolytic Virotherapy

2/2016	Trial Watch-Oncolytic viruses and cancer therapy.
1/2014	Trial Watch:: Oncolytic viruses for cancer therapy.
6/2013	Trial watch: Oncolytic viruses for cancer therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lorenzo Galluzzi Research Topics

Disease

240	Neoplasms (Cancer) 04/2024 - 01/2007
20	Carcinoma (Carcinomatosis) 10/2023 - 07/2008
19	Carcinogenesis 01/2023 - 01/2011
18	Breast Neoplasms (Breast Cancer) 10/2023 - 05/2012
13	Melanoma (Melanoma, Malignant) 01/2024 - 01/2014
13	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2019 - 07/2007
12	Necrosis 01/2017 - 02/2009
10	Disease Progression 10/2023 - 05/2012
10	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2023 - 02/2008
9	Inflammation (Inflammations) 01/2023 - 05/2009
8	Tetraploidy 05/2013 - 12/2007
5	Genomic Instability 01/2023 - 07/2010
5	Leukemia 11/2022 - 11/2012
5	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 05/2012
5	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2018 - 02/2008
4	Lung Neoplasms (Lung Cancer) 11/2023 - 08/2012
4	Hypoxia (Hypoxemia) 11/2022 - 06/2008
4	Obesity 01/2021 - 09/2013
4	Bites and Stings (Sting) 10/2020 - 01/2018
4	Infections 01/2020 - 06/2011
4	Starvation 10/2019 - 06/2008
3	Reperfusion Injury 03/2024 - 09/2013
3	Fibrosarcoma 11/2023 - 06/2013
3	Adenocarcinoma 10/2023 - 01/2020
3	Hematologic Neoplasms (Hematological Malignancy) 01/2023 - 06/2015
3	Virus Diseases (Viral Diseases) 01/2023 - 01/2007
3	Ovarian Epithelial Carcinoma 01/2022 - 01/2022
3	Triple Negative Breast Neoplasms 01/2021 - 10/2020
3	Prostatic Neoplasms (Prostate Cancer) 10/2013 - 10/2012
2	Chromosomal Instability (Chromosome Stability) 09/2023 - 12/2007
2	Squamous Cell Carcinoma of Head and Neck 01/2022 - 01/2020
2	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 01/2021

Drug/Important Bio-Agent (IBA)

34	Antineoplastic Agents (Antineoplastics)IBA 10/2023 - 01/2011
28	AntigensIBA 01/2024 - 10/2010
27	Immune Checkpoint InhibitorsIBA 03/2024 - 01/2017
23	VaccinesIBA 01/2022 - 03/2012
19	Proteins (Proteins, Gene)FDA Link 01/2023 - 07/2008
17	DNA (Deoxyribonucleic Acid)IBA 01/2024 - 11/2007
12	CytokinesIBA 09/2023 - 07/2012
11	Monoclonal AntibodiesIBA 01/2021 - 01/2012
10	Interferon Type IIBA 11/2023 - 01/2019
10	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2018
10	Adenosine Triphosphate (ATP)IBA 01/2021 - 06/2008
10	CalreticulinIBA 01/2021 - 12/2009
10	Cisplatin (Platino)FDA LinkGeneric 10/2014 - 12/2007
9	Therapeutic UsesIBA 11/2022 - 08/2012
9	Phosphotransferases (Kinase)IBA 01/2017 - 07/2008
8	AnthracyclinesIBA 01/2021 - 10/2010
8	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2021 - 03/2012
8	Peptides (Polypeptides)IBA 01/2021 - 12/2012
8	Toll-Like Receptor AgonistsIBA 01/2018 - 08/2012
7	Hormones (Hormone)IBA 10/2023 - 10/2012
6	EpitopesIBA 11/2023 - 01/2018
6	Pattern Recognition ReceptorsIBA 01/2022 - 02/2010
6	LigandsIBA 10/2020 - 10/2010
6	Erlotinib Hydrochloride (CP 358,774)FDA Link 09/2013 - 07/2007
5	Cytostatic AgentsIBA 01/2021 - 12/2015
5	Imiquimod (Aldara)FDA LinkGeneric 01/2020 - 08/2012
5	ErbB Receptors (EGF Receptor)IBA 09/2013 - 07/2007
4	RNA (Ribonucleic Acid)IBA 01/2024 - 01/2017
4	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2024 - 08/2012
4	InterferonsIBA 11/2023 - 01/2020
4	Chimeric Antigen ReceptorsIBA 01/2023 - 11/2015
4	PlatinumIBA 01/2022 - 01/2020
4	Phenobarbital (Luminal)FDA Link 01/2021 - 01/2020
4	CarcinogensIBA 01/2021 - 09/2012
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2020 - 03/2012
4	InterleukinsIBA 01/2020 - 03/2010
4	EnzymesIBA 01/2019 - 12/2011
4	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2014 - 03/2012
3	Reactive Oxygen Species (Oxygen Radicals)IBA 03/2024 - 01/2019
3	Mitochondrial DNA (mtDNA)IBA 01/2023 - 01/2005
3	Death Domain ReceptorsIBA 01/2023 - 10/2010
3	CarbohydratesIBA 12/2022 - 01/2018
3	Neoplasm Antigens (Tumor Antigens)IBA 01/2021 - 03/2011
3	Cyclin-Dependent Kinase 4IBA 01/2021 - 11/2020
3	HMGB1 Protein (HMG1)IBA 01/2019 - 03/2012
3	Formaldehyde (Formol)FDA Link 01/2018 - 08/2012
3	Protein Subunit VaccinesIBA 04/2015 - 12/2012
3	Vitamin B 6IBA 10/2014 - 08/2012
3	Mitoxantrone (Novantrone)FDA LinkGeneric 01/2014 - 03/2012
3	Gefitinib (Iressa)FDA Link 09/2013 - 12/2008
3	Digoxin (Digitek)FDA LinkGeneric 02/2013 - 07/2012
3	Cytotoxins (Cytolysins)IBA 08/2012 - 10/2010
3	Sirolimus (Rapamycin)FDA Link 01/2012 - 06/2008
2	Chloroquine (Aralen)FDA LinkGeneric 03/2024 - 01/2014
2	Glutathione (Reduced Glutathione)IBA 03/2024 - 08/2012
2	Green Fluorescent ProteinsIBA 03/2024 - 01/2013
2	Nucleic AcidsIBA 01/2024 - 11/2019
2	LTX-315IBA 01/2024 - 01/2021
2	Histocompatibility Antigens Class IIBA 11/2023 - 04/2013
2	Radioisotopes (Radionuclides)IBA 11/2023 - 01/2015
2	anthraceneIBA 10/2023 - 01/2020
2	Medroxyprogesterone Acetate (Depo-Provera)FDA LinkGeneric 10/2023 - 01/2020
2	cyclic guanosine monophosphate-adenosine monophosphateIBA 01/2022 - 01/2020

Therapy/Procedure

97	Therapeutics 04/2024 - 07/2008
40	Immunotherapy 03/2024 - 09/2012
37	Radiotherapy 04/2024 - 12/2007
30	Drug Therapy (Chemotherapy) 01/2022 - 01/2007
3	Oncolytic Virotherapy 02/2016 - 06/2013